Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer
An erratum to this article was published (J Clin Endocrinol Metab, 19 May 2025 ↗)
Authors' conclusion
CaboNivoIpi had low ORRs and a high rate of grade ≥3 treatment-related AEs.
Study context
- Population
- Patients with radioactive iodine-refractory DTC who progressed on 1 prior line of VEGFR-targeted therapy; median age 69 years10 evaluable
- Participants
- 11 patients
- Primary endpoint
- ORR
- Follow-up
- Within the first 6 months of treatment
Methodological detailsinvestigator-initiated, Simon optimal 2-stage design, prespecified interim analysis
- Investigator-initiated
- Simon optimal 2-stage design
- Prespecified interim analysis
Primary result
As reported in the abstract
ORR within the first 6 months of treatment
Objective response rate (ORR) among 10 evaluable patients
10%
1 partial response
Further findings
Progression-free survival
- Median PFS
- 9 months (95% CI, 3.0-not reached)
- Median follow-up 7.9 months
Overall survival
- Median OS
- 19.2 months (95% CI, 4.6-not reached)
Safety
Grade 3/4 treatment-related adverse events (AEs)
- Grade 3/4 treatment-related AEs
- 55% (6/11)
Grade 5 AEs
- Grade 5 AEs
- 18% (2/11)
Most common treatment-related AE
- Most common treatment-related AE was hypertension
Original publication
Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer. J Clin Endocrinol Metab. Published 12 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →